Clinical Pipeline
Shattuck’s Platform Combines Checkpoint Inhibition with TNF Costimulation
To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 400 preclinical bi-functional fusion protein drug candidates. The lead clinical-stage product candidate, SL-172154 (SIRPα-Fc-CD40L), is in two Phase 1 clinical trials. The first is for patients with platinum-resistant ovarian cancer (NCT04406623) with two cohorts, one evaluating SL-172154 in combination with a chemotherapy agent known as pegylated liposomal doxorubicin. The second cohort is evaluating SL-172154 in combination with an antibody drug conjugate known as mirvetuximab soravtansine, which targets an ovarian cancer antigen called folate receptor alpha. Shattuck’s second clinical development program is in hematologic malignancies (NCT05275439), evaluating SL-172154 in combination with azacitidine for patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS).
| Platform | Program | Domain 1 | Domain 2 | Indications | Combination Agents | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical-Stage Pipeline | ||||||||||
| ARC | SL-172154 | SIRPα | CD40L | Ovarian Cancer(1) | Liposomal Doxorubicin |
|
||||
| Mirvetuximab Soravtansine |
|
|||||||||
| AML and HR-MDS(2) | Azacitidine +/- Venetoclax |
|
||||||||
| Drug | Indication | Agents | Stage |
|---|---|---|---|
| SL-172154 | Ovarian Cancer(1) | Liposomal Doxorubicin | Phase 1 |
| Mirvetuximab Soravtansine | Phase 1 | ||
| SL-172154 | AML and HR-MDS(2) | Azacitidine +/- Venetoclax | Phase 1 |
| Multiple | Oncology | Preclinical | |
| Multiple | Oncology | Preclinical | |
| Autoimmune / Oncology | Preclinical |
(1) Advanced platinum-resistant ovarian cancer
(2) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
